AAPC CPC Exam With Confidence Using Practice Dumps

The operative service is anamputation of the left third toe at the metatarsophalangeal (MTP) joint. CPT28820describes toe amputationthrough the MTP joint, matching the “amputation at the metatarsophalangeal joint” language and the incision encircling the joint with removal of the toe after dividing tendons/ligaments. ModifierT2correctly identifies theleft foot, third digit. Diagnosis coding must capture the ischemic disease withgangreneplus thenon-pressure chronic ulceron the toe. In the answer set,I70.262represents lower-extremity atherosclerosis/PVDwith gangrene(left side per the option). The chronic ulcer is separately reported using the providedL97.528non-pressure ulcer code for the left foot/toe severity category offered by the choices. Antibiotic prophylaxis (Ancef), anesthesia type, tourniquet use/time, and technique details support the procedure but do not change the core CPT/ICD-10-CM selection. Therefore, the correct combination is28820-T2, I70.262, L97.528.

The Office of Inspector General (OIG) provides compliance program guidance to form the basis of a voluntary compliance program for provider practices. This guidance is intended to help healthcare providers develop effective internal controls to monitor adherence to applicable statutes, regulations, and program requirements of Federal healthcare programs. The OIG issues various compliance guidelines and resources to assist organizations in establishing comprehensive compliance programs to prevent fraud, waste, and abuse.

OIG Compliance Program Guidance, AMA ' s CPT® Professional Edition, and healthcare compliance resources.

Omalizumab is a drug reported withHCPCS J2357, and the dose is converted into billable units based on the code’s unit definition. In CPC-style questions,150 mgis commonly represented asJ2357 × 30 units(i.e., 5 mg per unit → 150/5 = 30). Administration is atherapeutic subcutaneous injection, reported with96372(therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular). Vaccine administration codes (90460/90471) are not appropriate because omalizumab is not a vaccine. For diagnosis, the statement includesstatus asthmaticusbut does not specify severity category (mild/moderate/severe persistent). In the options provided,J45.902is the “unspecified asthma with status asthmaticus” concept, whereas J45.52 requires severe persistent asthma with status asthmaticus (not documented). Therefore, the correct pairing is96372 + J2357 × 30 + J45.902. CPC exam tip: match administration code type (therapeutic injection vs immunization) and choose the most specific ICD-10-CM supported by documentation.